Current role of neprilysin inhibitors in hypertension and heart failure

Pharmacology and Therapeutics

Volumn 144, Issue 1, 2014, Pages 41-49

  Von Lueder, Thomas G ^a,b,c   Atar, Dan ^b,c   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Heart failure; Hypertension; Natriuretic peptide; Neprilysin; RAAS

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDOXATRIL; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GEMPATRILAT; ILEPATRIL; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; OLMESARTAN; OMAPATRILAT; SACUBITRIL; SAMPATRILAT; SLV 338; THIORPHAN; UNCLASSIFIED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR; CARDIOVASCULAR AGENT;

AIRWAY OBSTRUCTION; ANGIONEUROTIC EDEMA; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERTENSION; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84906937835     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.05.002     Document Type: Review

References (101)

1. Z.A. Abassi, J.E. Tate, E. Golomb, and H.R. Keiser Role of neutral endopeptidase in the metabolism of endothelin Hypertension 20 1992 89 95
2. E. Ambrosioni, C. Borghi, and B. Magnani The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators N Engl J Med 332 1995 80 85
3. S. Ando, M.A. Rahman, G.C. Butler, B.L. Senn, and J.S. Floras Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin Hypertension 26 1995 1160 1166
4. S. Bangalore, S. Kumar, J. Wetterslev, and F.H. Messerli Angiotensin receptor blockers and risk of myocardial infarction: Meta-analyses and trial sequential analyses of 147,020 patients from randomised trials BMJ 342 2011 d2234
5. E.G. Bevan, J.M. Connell, J. Doyle, H.A. Carmichael, D.L. Davies, and A.R. Lorimer et al. Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension J Hypertens 10 1992 607 613
6. M. Briet, and E.L. Schiffrin Aldosterone: Effects on the kidney and cardiovascular system Nat Rev Nephrol 6 2010 261 273
7. N.J. Brown Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis Nat Rev Nephrol 9 2013 459 469
8. F. Brunner, C. Bras-Silva, A.S. Cerdeira, and A.F. Leite-Moreira Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis Pharmacol Ther 111 2006 508 531
9. J.C. Burnett Jr.; J.P. Granger, and T.J. Opgenorth Effects of synthetic atrial natriuretic factor on renal function and renin release Am J Physiol 247 1984 F863 F866
10. D.J. Campbell Vasopeptidase inhibition: A double-edged sword? Hypertension 41 2003 383 389
11. D.J. Campbell, F. Anastasopoulos, A.M. Duncan, G.M. James, A. Kladis, and T.A. Briscoe Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats J Pharmacol Exp Ther 287 1998 567 577
12. A.S. Cerdeira, C. Bras-Silva, and A.F. Leite-Moreira Endothelin- converting enzyme inhibitors: their application in cardiovascular diseases Rev Port Cardiol 27 2008 385 408
13. H.H. Chen, J.A. Schirger, W.L. Chau, M. Jougasaki, O. Lisy, and M.M. Redfield et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure Circulation 100 1999 2443 2448
14. J.G. Cleland, and K. Swedberg Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators Lancet 351 1998 1657 1658
15. A. Clerico, F.A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: Physiological and clinical implications Am J Physiol Heart Circ Physiol 290 2006 H17 H29
16. P. Daull, O. Benrezzak, D. Arsenault, L.H. Pheng, A. Blouin, and J. Cayer et al. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats Am J Hypertens 18 2005 1606 1613
17. P. Daull, A. Blouin, K. Belleville, M. Beaudoin, D. Arsenault, and H. Leonard et al. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats Exp Biol Med (Maywood) 231 2006 830 833
18. K. Dickstein, H.J. De Voogd, M.P. Miric, R. Willenbrock, V. Mitrovic, and R. Pacher et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure Am J Cardiol 94 2004 237 239
19. V. Dive, C.F. Chang, A. Yiotakis, and E.D. Sturrock Inhibition of zinc metallopeptidases in cardiovascular disease - from unity to trinity, or duality? Curr Pharm Des 15 2009 3606 3621
20. N. Emoto, S.B. Raharjo, D. Isaka, S. Masuda, S. Adiarto, and A.Y. Jeng et al. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats Hypertension 45 2005 1145 1152
21. E.G. Erdos, and R.A. Skidgel Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones FASEB J 3 1989 145 151
22. C.J. Ferro, J.C. Spratt, W.G. Haynes, and D.J. Webb Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
23. I. Formentini, M. Bobadilla, C. Haefliger, G. Hartmann, M. Loghman-Adham, and J. Mizrahi et al. Current drug development challenges in chronic kidney disease (CKD) - identification of individualized determinants of renal progression and premature cardiovascular disease (CVD) Nephrol Dial Transplant 27 Suppl. 3 2012 iii81 iii88
24. H. Fujisaki, H. Ito, Y. Hirata, M. Tanaka, M. Hata, and M. Lin et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression J Clin Invest 96 1995 1059 1065
25. B. Geny, H. Hardy, J. Lonsdorfer, B. Eisenmann, P. Haberey, and F. Piquard Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients Hypertension 33 1999 969 974
26. S.R. Goldsmith Interactions between the sympathetic nervous system and the RAAS in heart failure Curr Heart Fail Rep 1 2004 45 50
27. J. Gu, A. Noe, P. Chandra, S. Al-Fayoumi, M. Ligueros-Saylan, and R. Sarangapani et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
28. W.G. Haynes, and D.J. Webb Endothelin as a regulator of cardiovascular function in health and disease J Hypertens 16 1998 1081 1098
29. L.G. Hegde, C. Yu, T. Renner, H. Thibodeaux, S.R. Armstrong, and T. Park et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat J Cardiovasc Pharmacol 57 2011 495 504
30. P.A. Heidenreich, N.M. Albert, L.A. Allen, D.A. Bluemke, J. Butler, and G.C. Fonarow et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association Circ Heart Fail 6 2013 606 619
31. M.V. Hoang, and A.J. Turner Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin Biochem J 327 Pt 1 1997 23 26
32. P.S. Jhund, B. Claggett, M. Packer, M.R. Zile, A.A. Voors, and B. Pieske et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial Eur J Heart Fail 2014 [Epub April 1, 2014]
33. P.S. Jhund, K. Macintyre, C.R. Simpson, J.D. Lewsey, S. Stewart, and A. Redpath et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: A population study of 5.1 million people Circulation 119 2009 515 523
34. P. Kalk, Y. Sharkovska, E. Kashina, K. von Websky, K. Relle, and T. Pfab et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner Hypertension 57 2011 755 763
35. K. Kario, N. Sun, F.T. Chiang, O. Supasyndh, S.H. Baek, and A. Inubushi-Molessa et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebo-controlled study Hypertension 63 2014 698 705
36. D.M. Kaye, and H. Krum Drug discovery for heart failure: A new era or the end of the pipeline? Nat Rev Drug Discov 6 2007 127 139
37. M. Knecht, I. Pagel, T. Langenickel, S. Philipp, M. Scheuermann- Freestone, and T. Willnow et al. Increased expression of renal neutral endopeptidase in severe heart failure Life Sci 71 2002 2701 2712
38. L. Kober, C. Torp-Pedersen, J.E. Carlsen, H. Bagger, P. Eliasen, and K. Lyngborg et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Engl J Med 333 1995 1670 1676
39. J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, and E. Levy Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
40. H. Krum, R. Denver, A. Tzanidis, and P. Martin Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure Heart Fail Rev 6 2001 341 352
41. H. Krum, and T. von Lueder Advances in Heart Failure Management 2012 Future Medicine Ltd. London, UK
42. T.W. Kurtz, and U. Klein Next generation multifunctional angiotensin receptor blockers Hypertens Res 32 2009 826 834
43. S. Kuruppu, N.W. Rajapakse, and A.I. Smith Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease Pflugers Arch 465 2013 929 934
44. M.P. Love, W.G. Haynes, G.A. Gray, D.J. Webb, and J.J. McMurray Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors Circulation 94 1996 2131 2137
45. K.B. Margulies, P.L. Barclay, and J.C. Burnett Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure Circulation 91 1995 2036 2042
46. P. Martin, A. Tzanidis, A. Stein-Oakley, and H. Krum Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction J Cardiovasc Pharmacol 36 2000 S367 S370
47. Y. Matsumura, T. Kuro, Y. Kobayashi, K. Umekawa, N. Ohashi, and M. Takaoka Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats Jpn J Pharmacol 84 2000 16 24
48. A.L. May, E.V. Kuklina, and P.W. Yoon Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008 Pediatrics 129 2012 1035 1041
49. G. McDowell, W. Coutie, C. Shaw, K.D. Buchanan, A.D. Struthers, and D.P. Nicholls The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides Br J Clin Pharmacol 43 1997 329 332
50. A.P. McGraw, A. McCurley, I.R. Preston, and I.Z. Jaffe Mineralocorticoid receptors in vascular disease: Connecting molecular pathways to clinical implications Curr Atheroscler Rep 15 2013 340
51. P.M. McKie, J.A. Schirger, L.C. Costello-Boerrigter, S.L. Benike, L.K. Harstad, and K.R. Bailey et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction J Am Coll Cardiol 58 2011 2095 2103
52. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, and K. Dickstein et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
53. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, and A.R. Rizkala et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 15 2013 1062 1073
54. V. Mellin, A.Y. Jeng, C. Monteil, S. Renet, J.P. Henry, and C. Thuillez et al. Triple ACE-ECE-NEP inhibition in heart failure: A comparison with ACE and dual ECE-NEP inhibition J Cardiovasc Pharmacol 46 2005 390 397
55. F.H. Messerli, and J. Nussberger Vasopeptidase inhibition and angio-oedema Lancet 356 2000 608 609
56. P. Mulder, S. Barbier, C. Monteil, A.Y. Jeng, J.P. Henry, and S. Renet et al. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure J Cardiovasc Pharmacol 43 2004 489 494
57. V.K. Munagala, J.C. Burnett Jr.; and M.M. Redfield The natriuretic peptides in cardiovascular medicine Curr Probl Cardiol 29 2004 707 769
58. L.J. Murphy, R. Corder, A.I. Mallet, and A.J. Turner Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1 Br J Pharmacol 113 1994 137 142
59. K. Nakayama, N. Emoto, Y. Suzuki, N. Vignon-Zellweger, K. Yagi, and K. Hirata Physiological relevance of hydrolysis of atrial natriuretic peptide by endothelin-converting enzyme-1 Kobe J Med Sci 58 2012 E12 E18
60. D.E. Newby, T. McDonagh, P.F. Currie, D.B. Northridge, N.A. Boon, and H.J. Dargie Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition Eur Heart J 19 1998 1808 1813
61. D.B. Northridge, P.F. Currie, D.E. Newby, J.J. McMurray, M. Ford, and N.A. Boon et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure Eur J Heart Fail 1 1999 67 72
62. D.B. Northridge, A.G. Jardine, C.T. Alabaster, P.L. Barclay, J.M. Connell, and H.J. Dargie et al. Effects of UK 69 578: A novel atriopeptidase inhibitor Lancet 2 1989 591 593
63. D.B. Northridge, D.E. Newby, E. Rooney, J. Norrie, and H.J. Dargie Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure Am Heart J 138 1999 1149 1157
64. G.R. Norton, A.J. Woodiwiss, C. Hartford, B. Trifunovic, S. Middlemost, A. Lee, and M.J. Allen Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects Am J Hypertens 12 1999 563 571
65. Novartis PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results. Novartis media release http://www.novartis.com/newsroom/media-releases/en/2014/1772754.shtml 2014
66. J.E. O'Connell, A.G. Jardine, G. Davidson, and J.M. Connell Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension J Hypertens 10 1992 271 277
67. C. Oefner, A. D'Arcy, M. Hennig, F.K. Winkler, and G.E. Dale Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon J Mol Biol 296 2000 341 349
68. M. Packer, R.M. Califf, M.A. Konstam, H. Krum, J.J. McMurray, J.L. Rouleau, and K. Swedberg Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
69. PARAGON-HF Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF) http://clinicaltrials.gov/ct2/show/NCT01920711 2013 (assessed Sept 27, 2013)
70. G. Parati, and M. Esler The human sympathetic nervous system: its relevance in hypertension and heart failure Eur Heart J 33 2012 1058 1066
71. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr.; and T.E. Cuddy et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 1992 669 677
72. L.R. Potter Natriuretic peptide metabolism, clearance and degradation FEBS J 278 2011 1808 1817
73. L.R. Potter, S. Abbey-Hosch, and D.M. Dickey Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions Endocr Rev 27 2006 47 72
74. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, and W.B. Borden et al. Executive summary: Heart disease and stroke statistics - 2012 update: A report from the American Heart Association Circulation 125 2012 188 197
75. B.P. Roques, F. Noble, V. Dauge, M.C. Fournie-Zaluski, and A. Beaumont Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology Pharmacol Rev 45 1993 87 146
76. J.L. Rouleau, M.A. Pfeffer, D.J. Stewart, D. Isaac, F. Sestier, and E.K. Kerut et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 2000 615 620
77. L.M. Ruilope, A. Dukat, M. Bohm, Y. Lacourciere, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
78. S.J. Sangaralingham, D.M. Heublein, J.P. Grande, A. Cataliotti, A.D. Rule, and P.M. McKie et al. Urinary C-type natriuretic peptide excretion: A potential novel biomarker for renal fibrosis during aging Am J Physiol Renal Physiol 301 2011 F943 F952
79. S.J. Sangaralingham, B.K. Huntley, F.L. Martin, P.M. McKie, D. Bellavia, and T. Ichiki et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide Hypertension 57 2011 201 207
80. Sanofi-Aventis AVE7688 in patients with mild to moderate blood pressure (RAVEL-1) 2013 U.S. National Institutes of Health 1 ((Vol. Accessed July 1, 2013). http://clinicaltrials.gov/ct2/show/study/NCT00284128?term= AVE7688&rank=1)
81. S.D. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, and E. Kraigher-Krainer et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
82. L.E. Spieker, and T.F. Luscher Endothelin receptor antagonists in heart failure - A refutation of a bold conjecture? Eur J Heart Fail 5 2003 415 417
83. R. Tabrizchi Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension Curr Opin Investig Drugs 9 2008 301 309
84. S. Telemaque, N. Emoto, D. deWit, and M. Yanagisawa In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats J Cardiovasc Pharmacol 31 Suppl. 1 1998 S548 S550
85. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
86. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
87. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
88. The SOLVD Investigattors Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
89. C. Thone-Reinke, K. Simon, C.M. Richter, M. Godes, H.H. Neumayer, and D. Thormahlen et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats J Cardiovasc Pharmacol 44 Suppl. 1 2004 S76 S79
90. N.C. Trippodo, M. Fox, T.M. Monticello, B.C. Panchal, and M.M. Asaad Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril J Cardiovasc Pharmacol 34 1999 782 790
91. L.C. van Vark, M. Bertrand, K.M. Akkerhuis, J.J. Brugts, K. Fox, and J.J. Mourad et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Eur Heart J 33 2012 2088 2097
92. T.G. von Lueder, and H. Krum RAAS inhibitors and cardiovascular protection in large scale trials Cardiovasc Drugs Ther 27 2013 171 179
93. T.G. von Lueder, S.J. Sangaralingham, B.H. Wang, A.R. Kompa, D. Atar, and J.C. Burnett Jr. et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: Novel therapeutic concepts to combat heart failure Circ Heart Fail 6 2013 594 605
94. E.J. Wallis, L.E. Ramsay, and J. Hettiarachchi Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension Clin Pharmacol Ther 64 1998 439 449
95. M. Watanabe, and H. Krum Eplerenone for the treatment of cardiovascular disorders Expert Rev Cardiovasc Ther 10 2012 831 838
96. M.A. Weber Vasopeptidase inhibitors Lancet 358 2001 1525 1532
97. M. Wegner, C. Hirth-Dietrich, and J.P. Stasch Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure Cardiovasc Res 31 1996 891 898
98. B. Williams, J.R. Cockcroft, K. Kario, D.H. Zappe, P. Cardenas, and A. Hester et al. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study BMJ Open 4 2014 e004254
99. K. Yamamoto, M.C. Chappell, K.B. Brosnihan, and C.M. Ferrario In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats Hypertension 19 1992 692 696
100. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, and Y. Mitsui et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415
101. F. Zannad, W. Gattis Stough, P. Rossignol, J. Bauersachs, J.J. McMurray, and K. Swedberg et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice Eur Heart J 33 2012 2782 2795